The cytochrome P450 enzyme system. A family with actions, reactions and interactions. Part 2;Een familie met acties, reacties en interacties. Deel 2. Het cytochroom P450-enzymsysteem

Pharmaceutisch Weekblad

Volumn 132, Issue 29, 1997, Pages 996-1009

  Touw, D J ^b   Breimer, D D ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NONE

Author keywords

cytochrome P 450; drug interactions; metabolism; polymorphism, genetic

Indexed keywords

CYTOCHROME P450; UNINDEXED DRUG;

DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME POLYMORPHISM; HUMAN; LIVER CELL; MICROSOME; REVIEW;

EID: 0030741316     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-50.
2. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;1:584-6.
3. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective oxidation of sparteine in man. A new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
4. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjøqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988;44:431-5.
5. Schellens JHM, Hermans J, Breimer DD. A 'cocktail' study design in the assessment of sparteine, mephenytoin and nifedipine metabolite distribution in a Dutch population. In: Schellens JHM. Characterization of human drug oxidation in vivo. [dissertatie]. Leiden: Rijksuniversiteit Leiden, 1988.
6. Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. Eur J Clin Pharmacol 1987;31:633-41.
7. Farrell GC, Murray M. Human cytochrome P450 isoforms. Their genetic heterogeneity and induction by omeprazole. Gastroenterology 1990;99:885-9.
8. Breimer DD. An integrated molecular and kinetic/dynamic approach to metabolism in drug development. In: Alvan G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Paintaud G, Pithan K, red. European cooperation in the field of scientific and technical research. COST B1 conference on variability and specificity in drug metabolism. Luxemburg: Office for official publications of the European Communities, 1995:3-19.
9. Pelkonen O, Breimer DD. Role of environmental factors in the pharmacokinetics of drugs: considerations with respect to animal models, P-450 enzymes, and probe drugs. In: Welling PG, Balant LP. Handbook of experimental pharmacology. Vol 110. Pharmacokinetics of drugs. Berlijn: Springer-Verlag, 1994:289-332.
10. Schellens JHM, Van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoine and antipyrine in humans as assessed by a 'cocktail' study design. J Pharmacol Exp Ther 1989;249:638-45.
11. Breimer DD, Schellens JHM. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990;11:223-5.
12. Inaba T, Vinks A, Otton SV, Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 1983;33:394-9.
13. Graf T, Broly F, Hoffman F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43:399-403.
14. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
15. Leclercq V, Desager JP, Van Nieuwenhuyze Y, Harvengt C. Prevalence of drug hydroxylator phenotypes in Belgium. Eur J Clin Pharmacol 1987;33:439-40.
16. Benitez J, Llerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 1988;44:74-7.
17. Spina E, Campo GM, Avenoso A, Caputi AP, Zuccaro P, Pacifici R, et al. CYP2D6-related oxidation polymorphism in Italy. Pharmacol Res 1994;29:281-9.
18. Orzechowska-Juzwenko K, Pawlik J, Niewinski P, Milejski P, Dembowski J, Turek J, et al. Genetically determined sparteine oxidation polymorphism in a Polish population [brief]. Eur J Clin Pharmacol 1994;46:481-3.
19. Kiivet RA, Svensson JO, Bertilsson L, Sjøqvist F. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacol Toxicol 1993;72:113-5.
20. Basci NE, Brøsen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. Br J Clin Pharmacol 1994;38:463-5.
21. Weerasuriya K, Jayakody RL, Smith CAD, Wolf CR, Tucker GT, Lennard MS. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994;38:466-70.
22. Horai Y, Taga J, Ishizaki T, Ishikawa K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990;29:111-5.
23. De Vane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55 suppl:38-45.
24. Bertilsson L, Dahl ML, Sjøqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63.
25. Koymans LMH, Vermeulen NPE, Van Acker SABE, Te Koppele JM, Heykants JJP, Lavrijsen K, et al. A predictive model for substrates of cytochrome P-450 debrisoquine (2D6). Chem Res Toxicol 1992;5:211-9.
26. Koymans LMH, Vermeulen NPE, Baarslag A, Donné-Op den Kelder G. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comput Aided Mol Des 1993;7:281-9.
27. Alvan G. Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 1991;5:209-28.
28. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46 suppl 1:417-24.
29. Dahl ML, Iselius L, Alm C, Svensson JO, Lee D, Johansson I, et al. Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 1993;44:445-50.
30. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990;18:346-64.
31. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40:543-9.
32. Nordin C, Siwers B, Benitez J, Bertilsson L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients. Relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985;19:832-5.
33. Mellstrøm B, Bertilsson L, Sawe J, Schulz HU, Sjøqvist F. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxlation. Clin Pharmacol Ther 1981;30:189-93.
34. Gram LF, Brøsen K, Kragh-Sorensen P, Christensen P. Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989;11:508-14.
35. Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
36. Laurent-Kenesi MA, Funck-Brentano C, Poirier JM, Decolin D. Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol 1993;36:531-8.
37. Lennard MS, Lewis RV, Brawn LA, Tucker GT, Ramsay LE, Jackson PR, et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 1989;27:429-34.
38. Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopentixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991;84:99-102.
39. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
40. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbø E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
41. Brøsen K. The pharmacokinetics of the selective serotonin reuptake inhibitors. Clin Invest 1993;71:1002-9.
42. Brøsen K, Gram LF, Kragh-Sorensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit 1991;13:177-82.
43. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
44. Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
45. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989;27:272-5.
46. Broly F, Vandamme N, Libersa C, Lhermitte M. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol 1991;32:459-66.
47. Feifel N, Kucher K, Fuchs L, Jedrychowsky M, Schmiedt E, Antonin KH, et al. Role of cytochrome P450IID6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol 1993;45:265-9.
48. Gross AS, Mikus G, Fischer C, Eichelbaum M. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol 1991;40:155-62.
49. Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropisetron. Ann Oncol 1993;4 suppl:S15-8.
50. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994;22:269-74.
51. Skjelbø E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
52. Skjelbø E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio): a population study. Br J Clin Pharmacol 1993;35:331-4.
53. Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
54. Brøsen K. The relationship between imipramine metabolism and the sparteine oxidation polymorphism. Dan Med Bull 1988;35:460-8.
55. Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991;49:609-17.
56. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988;43:400-6.
57. Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
58. Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986;31:449-55.
59. Balant-Gorgia AE, Balant L, Zysset Th. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. Eur J Clin Pharmacol 1987;32:101-2.
60. Nielsen KK, Brøsen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1992;43:405-11.
61. Funck-Brntano C, Turgeon J, Woosley R, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther 1989;249:134-42.
62. McAllister CB, Wolfenden HT, Aslanian WS, Woosley RL, Wilkinson GR. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica 1986;16:483-90.
63. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-14.
64. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
65. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993;43:120-6.
66. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
67. Smith RL. β-Blockers and genetic polymorphism. Polymorphic metabolism of the β-adrenoreceptor blocking drugs and its clinical relevance. Eur J Clin Pharmacol 1985;28 suppl:77-84.
68. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
69. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Bijsterveldt L, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55 suppl:13-7.
70. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994;47 suppl 1:3-7.
71. Firkusny L, Gleiter CH. Maprotiline metabolism appears to cosegregate with the genetically determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994;37:383-8.
72. Dahl ML, Tybring G, Elwin CE, Alm C, Andreasson K, Gyllenpalm M, et al. Stereoselective disposition of mianserin is related to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 1994;56:176-83.
73. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991;31:381-90.
74. Mikus G, Somogyi AA, Bochner F, Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol 1991;41:757-62.
75. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;2:914-5.
76. Mellstrom B, Bertilsson L, Lou YC, Sawe J, Sjøqvist F. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1983;34:516-20.
77. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
78. Caporaso NE, Shaw GL. Clinical implications of the competitive inhibition of the debrisoquine-metabolizing isozyme by quinidine. Arch Intern Med 1991;151:1985-92.
79. Kupfer A, Patwardhan R, Ward S, Schenker S, Preisig R, Branch RA. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (Nirvanol) in humans. J Pharmacol Exp Ther 1984;230:28-33.
80. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
81. Hadidi HF, Irshaid YM, Woosley RL, Idle JR, Flockhart DA. S-Mephenytoin hydroxylation phenotypes in a Jordan population. Clin Pharmacol Ther 1995;58:542-7.
82. Reviriego J, Bertilsson L, Carillo JA, Llerena A, Valdivielso MJ, Benitez J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol 1993;44:593-5.
83. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9.
84. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 1994;56:142-53.
85. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relation to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
86. Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301.
87. Reilly PE, Thompson DA, Mason SR, Hooper WD. Cytochrome P450IIIA enzymes in rat liver microsomes: involvement in C3-hydroxylation of diazepam and nordazepam but not in N-dealkylation of diazepam and temazepam. Mol Pharmacol 1990;37:767-74.
88. Zhang Y, Reviriego J, Lou YQ, Sjøqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990;48:496-502.
89. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and in Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993;53:608-9.
90. Spina E, Buemi AL, Sanz E, Bertilsson L. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotypeing tests. Ther Drug Monit 1989;11:721-3.
91. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979;28:41-51.
92. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: characterisation of the form of cytochrome P-450 involved in methylhydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987;241:1112-9.
93. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994;37:205-7.
94. Ward SA, Helsby NA, Skjelbø E, Brøsen K, Gram L, Breckenridge AM. The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism. A panel study. Br J Clin Pharmacol 1991;31:689-92.
95. Brøsen K, Skjelbø E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
96. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994;37:413-20.
97. Wang JP, Unandhat JD, McNamara S, O'Sullivan TA, Smith AL, Trager WF, et al. Disposition of drugs in cystic fibrosis. VI. in vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1994;55:528-34.
98. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and a inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
99. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
100. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and orientals. Ther Drug Monit 1994;16:214-5.
101. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, et al. Omeprazole is an arylhydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990;99:737-47.
102. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994;269:384-92.
103. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A4 by omeprazole. Clin Pharmacol Ther 1996;60:396-404.
104. Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995;58:62-72.
105. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450IIC8. Cancer Res 1994;54:5543-6.
106. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
107. Kohler DR, Goldspiel BR. Paclitaxel (Taxol). Pharmacotherapy 1994;14:3-38.
108. Zhao J, Leeman T, Dayer P. In vitro oxidation of oxicam NSAID by a human liver cytochrome P450. Life Sci 1992;51:575-81.
109. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
110. Hunt CM, Westerkam WR, Stave GM, Wilson JA. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64:189-99.
111. Ribeiro V, Lechner MC. Cloning and characterization of a novel CYP3A1 allelic variant: analysis of CYP3A1 and CYP3A2 sex-hormone-dependent expression reveals that the CYP3A2 gene is regulated by testosterone. Arch Biochem Biophys 1992;293:147-52.
112. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988;37:2507-10.
113. Soons PA, Schellens JHM, Breimer DD. Variability in pharmacokinetics and metabolism of nifedipine and other dihydropyrimidine calcium entry blockers. In: Kalow W, red. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:769-89.
114. Bocker RH, Guengerich FP. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J Med Chem 1986;29:1596-603.
115. Kronbach T, Mathys D, Umeno M, Gonzales FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
116. Dundee JW, Collier PS, Carlisle RJT, Harper KW. Prolonged midazolam elimination half-life. Br J Clin Pharmacol 1986;21:425-29.
117. Kassai A, Toth G, Eichelbaum M, Klotz U. No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet 1988;15:319-25.
118. Olkkola KT, Aranko K, Luurila H, Hiller A, Saanivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
119. Olkkola K, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
120. Biglin KE, Faraon MS, Consyance TD, Lieh-Lai M. Drug induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994;28:282.
121. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1550-2.
122. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
123. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J Clin Invest 1989;83:688-97.
124. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant patients. Clin Pharmacol Ther 1992;52:471-8.
125. Pippenger CE. Clinically significant carbamazepine drug interactions: an overview. Epilepsia 1987;28 suppl:S71-6.
126. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
127. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
128. Berkovitch M, Bitzan M, Matsui D, Finkelstein H, Balfe JW, Koren G. Pediatric clinical use of the ketoconazole/cyclosporin interaction. Pediatr Nephrol 1994;8:492-3.
129. Crocker JF, Renton KW, LeVatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol 1994;8:408-11.
130. Brockmoller J, Neumayer HH, Wagner K, Weber W, Heinemeyer G, Kewitz H. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990;38:237-42.
131. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
132. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
133. Bachman K, Chu CA, Grear V. in vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology 1992;45:121-8.
134. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal functions. Drug Metab Dispos 1993;21:978-85.
135. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 1993; 21: 645-656.
136. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37.
137. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen O, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol 1994;270:35-43.
138. Greenblatt DJ. Interaction of triazolam and ketoconazol. Lancet 1995;345:191.
139. Greenblatt DJ, Von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry 1993;54 suppl:4-11.
140. Petersen KU. Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995;9:1-9.
141. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, et al. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992;2:173-83.
142. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994;3:413-21.
143. Bachmann K, Sanyal G, Potter J, Schavione R, Loch J. in vivo evidence that theophylline is metabolized principally by CYP1A in rats. Pharmacology 1993;47:1-7.
144. Bertilsson L, Carillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
145. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose related plasma-levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989;99 suppl:S38-40.
146. Touw DJ. Metabolisme van clozapine. Een analyse van de variabelen welke het metabolisme van clozapine kunnen beïnvloeden. Pharm Weekbl 1995;130:256-62.
147. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
148. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
149. Carillo JA, Dahl M-L, Svensson J-O, Alm C, Rodriguez I, Bertilsson L Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
150. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP1E2 activity. Clin Pharmacol Ther 1995;58:498-505.
151. Breimer DD. Drug-drug interactions mediated by induction of metabolism. In: Breimer DD, Merkus FWHM, red. Drug-drug and drug-food interactions. Leiden: Boerhaave committee for postgraduate medical education, 1991:35-58.
152. Syvalahti EKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89-92.
153. Gram LF, Overo KF, Kirk L. Influence of neuroleptics and benzodiazpines on metabolism of tricyclic antidepressants in man. Am J Psychiatry 1974;131:8.
154. Gram LF, Overo KF. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972;71:463-5.
155. Nelson JC, Jatlow PI. Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 1980;137:1232-4.
156. Hirschowitz J, Bennett JA, Zemlan FP, Garver DL. Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol 1983;3:376-9.
157. Touw DJ. Metabolisme van clomipramine. Pharm Weekbl 1992;127:1068-74.
158. Brøsen K, Skjelbø E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
159. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
160. Muller N, Brockmoller J, Toots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele - a slowly reversible interaction with fluoxetine. Ther Drug Monit 1991;13:533-6.
161. Shader RI, Greenblatt DJ, Von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-6.
162. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-8.
163. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentration after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-5.
164. Woolfrey S, Gammack NS, Dewar MS, Brown PJE. Fluoxetine-warfarin interaction. Br Med J 1993;307:241.
165. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo: Professional Communications, 1996:184.
166. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
167. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991;6:460-2.
168. Van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994;151:1289-90.
169. Unsorg FJ, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4.
170. Daniel DG, Randolph C, Jasskin G, Handel S, Williams T, Abi-Dargham A, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
171. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
172. Bertschy G, Vandel S, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction: an accidental finding [brief]. Eur J Clin Pharmacol 1991;40:119-20.
173. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15:243-6.
174. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by
175. Barros J, Asnis G. An interaction of sertraline and desipramine. Am J Psychiatry 1993;150:1751.
176. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993;150:1125-6.
177. Gram LF, Brøsen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-52.
178. Jerling M, Bertilsson L, Sjøqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
179. Brøsen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993;15:258-60.
180. Otani K, Ishida M, Kaneko S, Mihara K, Okhubo T, Osanai T, et al. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 1996;18:164-7.
181. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996;18:60-4.
182. Schellens JHM, Ghabrial H, Van der Wart HHF, Bakker EN, Wilkinson GR, Breimer DD. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991;50:520-8.
183. Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 1988;43:577-81.
184. Philip PA, James CA, Rogers HJ. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Eur J Clin Pharmacol 1989;36:319-21.
185. 2-receptor antagonists. Am Pharm 1991;31:29-35.
186. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991;36:1665-9.
187. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolisers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
188. Soto J, Sacristan JA, Alsar MJ. Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease. Ther Drug Monit 1994;16:49-52.
189. Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet 1980;2:978.
190. Silver JM, Yudofsky SC, Kogan M, Katz BL. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986;143:1290-2.
191. Tollefson G, Lesar T. Effect of propranolol on maprotiline clearance. Am J Psychiatry 1984;141:148-9.
192. Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sergeant HGS. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977;2:575-8.
193. Bailey DG, Bend JR, Arnold MO, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33.
194. Drug interactions predisposing to ventricular arrhythmias. WHO Drug Information 1996;10:85-6.
195. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycine and terfenadine: Lack of drug interaction. Clin Pharmacol Ther 1995;48:310-5.
196. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
197. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-9.
198. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990;113:799-800.
199. Sorgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 2: Renal and hepatic elimination pathways and drug interactions. Am J Med 1993;94 suppl 3A:56S-69S.
200. McLellan RA, Drobitch RK, McLellan DH, Acott PD, Crocker JFS, Renton KW. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995;58:322-7.
201. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;52:231-8.
202. Transon C, Leemann T, Vogt N, Dayer P. in vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995;58:412-7.
203. Burger DM, Hoetelmans RMW. Klinisch relevante geneesmiddelinteracties met antiretrovirale middelen. Pharm Weekbl 1996;131:1232-4.
204. Antiretrovirale middelen. In: Informatorium Medicamentorum. 1977. 's-Gravenhage: KNMP 1997:300-5.
205. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992;152:711-6.
206. Backman JT, Olkkola KT, Neuvonen PJ. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
207. Bailey DG, Spence JD, Munzo C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
208. Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991;50:394-403.
209. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6.
210. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahlenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
211. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.